Enzo Biochem EPS - Earnings per Share 2010-2023 | ENZ
Enzo Biochem eps - earnings per share from 2010 to 2023. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Enzo Biochem Annual EPS |
| 2022 |
$-0.38 |
| 2021 |
$0.16 |
| 2020 |
$-0.60 |
| 2019 |
$0.05 |
| 2018 |
$-0.22 |
| 2017 |
$-0.05 |
| 2016 |
$0.97 |
| 2015 |
$-0.05 |
| 2014 |
$-0.23 |
| 2013 |
$-0.46 |
| 2012 |
$-1.01 |
| 2011 |
$-0.34 |
| 2010 |
$-0.59 |
| 2009 |
$-0.63 |
| Enzo Biochem Quarterly EPS |
| 2023-01-31 |
$-0.23 |
| 2022-10-31 |
$-0.22 |
| 2022-07-31 |
$-0.18 |
| 2022-04-30 |
$-0.10 |
| 2022-01-31 |
$-0.05 |
| 2021-10-31 |
$-0.05 |
| 2021-07-31 |
$0.06 |
| 2021-04-30 |
$0.04 |
| 2021-01-31 |
$0.05 |
| 2020-10-31 |
$0.01 |
| 2020-07-31 |
$-0.07 |
| 2020-04-30 |
$-0.21 |
| 2020-01-31 |
$-0.16 |
| 2019-10-31 |
$-0.16 |
| 2019-07-31 |
$-0.11 |
| 2019-04-30 |
$0.47 |
| 2019-01-31 |
$-0.18 |
| 2018-10-31 |
$-0.13 |
| 2018-07-31 |
$-0.13 |
| 2018-04-30 |
$-0.06 |
| 2018-01-31 |
$-0.02 |
| 2017-10-31 |
$-0.01 |
| 2017-07-31 |
$0.00 |
| 2017-04-30 |
$0.00 |
| 2017-01-31 |
$-0.02 |
| 2016-10-31 |
$-0.03 |
| 2016-07-31 |
$0.77 |
| 2016-04-30 |
$-0.05 |
| 2016-01-31 |
$0.15 |
| 2015-10-31 |
$0.10 |
| 2015-07-31 |
$0.18 |
| 2015-04-30 |
$-0.06 |
| 2015-01-31 |
$-0.09 |
| 2014-10-31 |
$-0.08 |
| 2014-07-31 |
$-0.06 |
| 2014-04-30 |
$-0.01 |
| 2014-01-31 |
$-0.09 |
| 2013-10-31 |
$-0.07 |
| 2013-07-31 |
$-0.08 |
| 2013-04-30 |
$-0.15 |
| 2013-01-31 |
$-0.14 |
| 2012-10-31 |
$-0.09 |
| 2012-07-31 |
$-0.69 |
| 2012-04-30 |
$-0.09 |
| 2012-01-31 |
$-0.11 |
| 2011-10-31 |
$-0.12 |
| 2011-07-31 |
$-0.11 |
| 2011-04-30 |
$-0.05 |
| 2011-01-31 |
$-0.15 |
| 2010-10-31 |
$-0.03 |
| 2010-07-31 |
$-0.15 |
| 2010-04-30 |
$-0.12 |
| 2010-01-31 |
$-0.27 |
| 2009-10-31 |
$-0.05 |
| 2009-07-31 |
$-0.15 |
| 2009-04-30 |
$-0.11 |
| 2009-01-31 |
$-0.20 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.106B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
